NCT04631029 2025-10-03Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has SpreadNational Cancer Institute (NCI)Phase 1 Completed3 enrolled 12 charts
NCT03250273 2025-05-28A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic AdenocarcinomaSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 Completed44 enrolled 19 charts
NCT01349959 2025-04-27Azacitidine and Entinostat in Treating Patients With Advanced Breast CancerNational Cancer Institute (NCI)Phase 2 Completed58 enrolled 16 charts
NCT02437136 2025-03-20Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)Syndax PharmaceuticalsPhase 1/2 Completed191 enrolled 26 charts